Voyageur Pharmaceuticals Ltd.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Brent Willis
- Full Time Employees
- 6
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 339–50th Avenue SE Calgary AB Canada T2G 2B3
- IPO Date
- Oct 19, 2017
- Website
- voyageurminerals.ca
- Similar Companies
- Business
- Voyageur Pharmaceuticals Ltd. develops and manufactures mineral-based active pharmaceutical ingredients and contrast media products for medical imaging applications, including barium sulfate suspensions and iodine-based agents for CT, fluoroscopy, MRI, and ultrasound procedures. The Canada-based company, founded in 2013 and headquartered in Calgary, Alberta, offers a portfolio of Health Canada-licensed barium products such as Smooth HD, Smooth X, Smooth LD, Vision HD, Vision LD, and V-Gas; it also pursues iodine APIs, endohedral fullerene contrast agents, and vertically integrated production from raw mineral sourcing in British Columbia, Canada, and Utah, USA, targeting North American healthcare providers amid supply chain vulnerabilities. Formerly Voyageur Minerals Ltd. until its rebranding in December 2019, the company has pursued strategic expansions including a December 2024 letter of intent with a multinational contrast media firm for production efficiencies and market entry, expected to finalize in early 2025; a March 2024 alliance with Applied Pharmaceutical Innovations for carbon-based imaging technologies; a June 2025 memorandum of understanding with Altillion to advance North America's first integrated iodine drug supply; a October 2025 non-exclusive distribution agreement with Phalanx for U.S. wholesale; and a June 2025 LOI for Latin America distribution covering Mexico and other countries, alongside preparations for 2025 barium product launches, FDA licensing pursuits, human testing of itsium contrast, CAD 2.7 million sales agreements, and new fullerene drug development programs.
Voyageur Pharmaceuticals Announces the Engagement of Red Cloud Securities as Market Maker
Voyageur Pharmaceuticals Engages Fluor to Advance Feasibility Studies for Iodine Production and Integrated Contrast Drug Manufacturing Facility
Voyageur Pharmaceuticals Evaluating Three Locations in the United States for Integrated Iodine and Barium Contrast Media Manufacturing Facility, a Multi-Phase Investment Expected to Generate Significant Economic Impact and High-Skilled Jobs; Competitive Site Selection Process Underway
Voyageur Pharmaceuticals Ltd. Submits Multi-Year Area-Based Exploration Permit Application for Bulk Sampling and Feasibility Support at Frances Creek Barite Project
Voyageur Announces Closing Of Non-Brokered Private Placement Pursuant To Listed Issuer Financing Exemption
Voyageur Announces Update To Non-Brokered Life Offering
Voyageur Pharmaceuticals Confirms Pharmaceutical-Grade Purity of Barite from Frances Creek and Progresses to Health Canada Human Trial with Alberta Innovates Grant; Announces Stock Option and DSU grants, and Proposed Issuance of Securities for Debt
Voyageur Pharmaceuticals Announces Collaboration with Bayer
Voyageur Pharmaceuticals Strengthens Scientific Team by Adding Dr. Brian Mueller as Director of Chemistry and Secures Exclusive Ownership of Iodine Extraction Technology
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Seasoned Financial Executive Virginia Alling to Drive U.S. Market Expansion
Voyageur Pharmaceuticals Signs Non-Exclusive Distribution & Wholesale Agreement with PHALANX
Voyageur Pharmaceuticals Ltd. Strengthens Board of Directors with Wall Street Expertise to Facilitate U.S. Market Expansion
Voyageur Pharmaceuticals Launches U.S. Iodine Feasibility Study to Establish First Fully Integrated North American Contrast Drug Manufacturing Platform
Voyageur Pharmaceuticals Initiates First Commercial Shipments of Barium Contrast Products to Canadian Clinics
Voyageur Pharmaceuticals Announces Exercise of Warrants for Gross Proceeds of $1.69 Million
Voyageur Pharmaceuticals partners with VAST on Frances Creek permitting work
Voyageur Advances Frances Creek Barite Project with VAST Engagement for Bulk Sample Permit
Voyageur Pharmaceuticals Grants Deferred Share Units and Options and Accelerates Expiry Date of Warrants
Voyageur Pharmaceuticals Signs LOI for Latin America Distribution Partnership Supporting Global Market Expansion
Voyageur Pharmaceuticals books first commercial sale with barium contrast agents order